GSK pointed out that the latest ruling ruling does not mean that the Court agrees with plaintiffs’ experts’ scientific conclusions, and it does not determine liability. Credit: viewimage / Shutterstock.com.

The US Food and Drug Administration (FDA) has granted fast track designation to GSK’s bepirovirsen, an investigational treatment for chronic hepatitis B (CHB).

A triple-action antisense oligonucleotide (ASO), bepirovirsen is being analysed in a Phase III B-Well clinical trial programme.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It acts on and degrades the genetic components of the hepatitis B virus (HBV), enabling the immune system to combat the virus more effectively.

Bepirovirsen works by inhibiting viral DNA replication, suppressing hepatitis B surface antigen (HBsAg) levels and stimulating immune response.

The fast track status was supported by data from Phase IIb trials, B-Clear and B-Sure, which assessed the safety, efficacy and response durability of bepirovirsen in individuals with CHB.

The B-Clear trial included two cohorts, one consisting of subjects on nucleoside/nucleotide analogues (NAs) treatment and the other of participants not on NAs.

B-Sure is a follow-up study extending 33 months beyond B-Clear, to determine the lasting efficacy and response durability, including the potential for a functional cure in people who stop all medications and show no signs of HBsAg or HBV DNA.

Bepirovirsen is the only monotherapy in Phase III development stage that has demonstrated the potential to attain a clinically meaningful functional cure along with oral NAs, as evidenced by the positive outcomes from the B-Clear and B-Sure trials.

It is being explored as a foundational therapy in future sequential treatment regimens aimed at achieving a functional cure in a wider patient population with CHB.

Discovered and co-developed by GSK and Ionis Pharmaceuticals, bepirovirsen is among the ASO HBV programme assets in-licensed by GSK from Ionis Pharmaceuticals in August 2019.

Last month, GSK agreed to acquire asthma drug specialist Aiolos Bio in a $1.4bn deal as it aims to strengthen its respiratory and inflammatory asset pipeline.